PRZOOM - /newswire/ -
Stoke-on-Trent, Staffordshire, United Kingdom, 2008/07/07 - Blackstar Internet Ltd today announced the launch of Pharmaetrade.com - The worlds premier pharmaceutical trading platform.
Pharmaetrade.com has been designed for manufacturers, distributors, wholesalers, import/exporters and retailers of branded drugs, Generics, medical equipment and OTC products.
Pharmaetrade.com is the only industry specific online platform that allows you to advertise your company, post stock requirements and stock for sale, keep up to date with industry news, promote new products, form new business relationships in a global arena, Increase your margins & volumes and stay in touch with your client base using a free online messenger service all from one point.
Nick Greer Managing Director said ‘The launch of Pharmaetrade.com is testament to our commitment to bring a world class Pharmaceutical Trading Platform to market supported by our value added services’
Parallel distribution of pharmaceuticals, as well as for other goods, stems from price differentials between different national markets within the European Economic Area (EEA). Parallel distributors buy products marketed by the original manufacturer at a lower price in one country and sell them at a higher price in another country. Such a form of trade is legal by virtue of the rule of regional exhaustion of trademark rights applied in the EU and the EEA.
Parallel distribution of medicines provides significant savings to governments, health insurers and patients by making original, innovative medicines available at a lower cost.
A 2005 study of only four EU countries found that parallel distribution generated direct savings to patients and social health insurance systems in excess of €440 million in 2004. It also found that there are significant indirect savings through the competitive effect of parallel distribution.
The British, German, Dutch, Danish, Swedish and Norwegian healthcare systems make direct savings of hundreds of million of Euros every year thanks to parallel-traded medicines.
To these direct savings must be added a much higher amount of indirect savings as a result of parallel trade being the only form of price competition to monopolistic patent-protected brands.
Without parallel trade, healthcare contributions by the tax-payer would be higher and many patients would face paying more at a time of growing need for prescribed medicines.
With newer and improved medicines increasingly expensive, and with the range of parallel-traded products expanding with more countries involved as parallel trade destinations, there is a huge potential for savings to increase - as long as supplies are not jeopardised by artificial barriers - such as quota systems or dual pricing by manufacturers - to free movement within the EU.
Source: European Association of Euro-Pharmaceutical Companies
Pharmaetrade.com is a service provided by:
Blackstar Internet Ltd
Unit 12 Hampton St, Joiners Square Industrial Estate,
Stoke-On-Trent, Staffordshire ST1 3EX